HEPHAISTOS-Pharma, an Orsay, France-based biotechnology company developing next generation immunotherapies against cancer, raised €2m in seed funding.
The round was co-led by xista science ventures and the Foundation Fournier-Majoie, with the participation of Noshaq.Led by Frederic Caroff, CEO, and co-founder, the company intends to use the funds to finance GMP transfer and advance its lead candidate towards the clinic. The proceeds from this financing round will enable HEPHAISTOS to industrialize its manufacturing process and prepare for the clinical phases, with the goal of advancing its lead candidate, ONCO-Boost, into clinical development for the treatment of solid tumors with high unmet medical needs, in particular sarcoma. The proceeds will also be used to open a new subsidiary in Liège, Wallonia. The objective will be to leverage local state-of -the-art facilities and expertise to explore additional applications and strengthen HEPHAISTOS’ pipeline.24/01/2024
